AVANIR PHARMACEUTICALS (AVN) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 15 transactions totaling $6.2M, demonstrating a bearish sentiment with -$6.2M in net insider flow. The most recent transaction on May 31, 2006 involved a sale of 629,121 shares valued at $6.2M.
No significant insider buying has been recorded for AVN in the recent period.
No significant insider selling has been recorded for AVN in the recent period.
Based on recent SEC filings, insider sentiment for AVN is bearish with an Insider Alignment Score of 0/100 and a net flow of -$6.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at AVANIR PHARMACEUTICALS (AVN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading AVN stock, having executed 15 transactions in the past 90 days. The most active insider is Capital II Llc Orbimed (Executive), who has made 1 transactions totaling $6.2M.
Get notified when executives and directors at AVN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| May 31, 2006 | II Llc Orbimed Capital | Executive | Sale | 629,121 | $9.79 | $6.2M | Large |
| May 31, 2006 | D. Isaly Samuel | Executive | Other | 629,121 | $9.79 | $6.2M | Large |
| Feb 17, 2006 | C. Sircar Jagadish | Executive | Sale | 3,600 | $16.82 | $60.6K | |
| Feb 17, 2006 | C. Sircar Jagadish | Executive | Option Exercise | 5,000 | $12.00 | $60.0K | |
| Feb 14, 2006 | J. Mazzo David | Executive | Purchase | 1,000 | $15.59 | $15.6K | |
| Feb 13, 2006 | J. Mazzo David | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | Podlesak Dennis | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | Thomas Paul | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | A. Wheeler Craig | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | M. Whitcup Scott | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | G. Austin Stephen | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | Mathews Charles | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | Silverstein Jonathan | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | Llc Orbimed Advisors | Executive | Award | 6,435 | $N/A | $0 | |
| Feb 13, 2006 | Llc Orbimed Advisors | Executive | Award | 2,335,258 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 2 | $6.2M | 49.9% |
Other(J) | 1 | $6.2M | 49.5% |
Exercise(M) | 1 | $60.0K | 0.5% |
Purchase(P) | 1 | $15.6K | 0.1% |
Award(A) | 10 | $0 | 0.0% |
Insider selling pressure at AVANIR PHARMACEUTICALS has increased, with 12 insiders executing 15 transactions across all time. Total sales of $6.2M significantly outpace purchases of $15.6K, resulting in a net outflow of $6.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.